Overview

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.

Phase:

Phase 2

Details

Lead Sponsor:

Edward Chu, MD
University of Pittsburgh

Collaborator:

Kadmon Pharmaceuticals

Treatments:

Camptothecin
Irinotecan